AINULT TERVISHOIUTÖÖTAJATELE

See veebileht on mõeldud ainult tervishoiutöötajatele.

See veebileht sisaldab teavet Foundation Medicine® testide kohta, ent ei ole mõeldud meditsiiniliste nõuannete ja / või ravijuhiste pakkumiseks.

Selle veebilehe on loonud Roche kui Roche Foundation Medicine partner.

!
Kasutame leheküljel küpsiseid, et tagada teile parim külastuskogemus. Kasutades meie lehekülge, nõustute küpsiste kasutamisega vastavalt meie küpsiste eeskirjadele.
×
Menu
Close
Orange
Meie testidFoundationOne CDxFoundationOne Liquid CDxFoundationOne Heme

 

 

 

 

Vähigenoomi test hematoloogiliste kasvajate ja sarkoomide täpsemaks diagnoosimiseks, prognoosi hindamiseks ja personaalse ravi valikuks.1

Tellimine

FoundationOne Heme tellimine

Testimiseks sobivad erinevad koematerjalid: formaliinis fikseeritud parafiini sisestatud koetükk (FFPE), perifeerne täisveri või luuüdi aspiraat. Vere ja luuüdi aspiraat tuleb optimaalse analüüsitulemuse saamiseks laborisse edastada samal päeval vere- või luuüdi võtuga. 
FoundationOne Heme preparaadi ettevalmistamise juhend FoundationOne Heme preparaadi ettevalmistamise juhend
FoundationOne Heme tehniline teave FoundationOne Heme tehniline teave

FFPE, formaliinis fikseeritud parafiini sisestatud. MSI,mikrosatelliitide ebastabiilsus, TMB, kasvaja mutatsioonide koormus

Testid on mõeldud professionaalseks kasutamiseks. Foundation Medicine testid on Euroopa Liidus registreeritud in vitro diagnostikameditsiiniseadmetena vastavalt Euroopa Parlamendi ja nõukogu direktiivile 98/79/EÜ

References
  1. FoundationOne®Heme Technical Specifications, 2020. Leitav: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
  2. He J et al. Blood 2016; 127: 3004–3014.
  3. Gounder M et al. Presented at ASCO Annual Meeting 2017, Chicago (Illinois), USA: Abstract #11001 and oral presentation.
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Lymphoblastic Leukaemia. V.1.2018, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Myeloid Leukaemia. V.1.2019, 2019. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  6. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myelodysplastic Syndromes. V.2.2019, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple Myeloma. V.2.2019, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). B-cell Lymphoma. V.1.2019, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). T-cell Lymphoma. V.2.2019, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myeloproliferative Neoplasms. V.2.2019, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Lymphocytic Leukaemia. V.5.2019, 2018. Leitav: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed July 2020).
  12. Morley S et al. Blood 2015; 126: 3898.
  13. Kobos R et al. Presented at ASH Annual Meeting 2016, San Diego (California), USA: Abstract 1605.
  14. He J et al. Presented at ASH Annual Meeting 2015, Orlando (Florida), USA: Abstract 2651.
  15. Galanina N et al. Cancers (Basel) 2018; 11.pii: E11.
  16. Goodman AM et al. JCO Precis Oncol 2017. doi: 10.1200/PO.16.00004. 
  17. Heuck C et al. Blood 2015; 126: 369.
  18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Soft Tissue Sarcoma. V.2.2019, 2019. Leitav: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx (Accessed July 2020).
  19. Groisberg R et al. Oncotarget 2017; 8: 39254–39267.
  20. Doyle LA et al. Cancer 2014; 120: 1763–1774.
  21. Cote GM et al. Oncologist 2018; 23: 234–242.
  22. Chmielecki J et al. Cancer Res 2017; 77: 509–519.
  23. FoundationOne Heme Sample Draft Report
    https://images.ctfassets.net/w98cd481qyp0/2XACCJ2FjtSdNP5ioTunxR/e9231969ebb6c9a6a5ebfa689bc21555/Acute_Myeloid_Leukemia__AML__Sample_Report_-_FoundationOne_Heme.pdf
  24. Chavan SS et al. Blood Cancer J 2017; 7: e535.
  25. Severson EA et al. Presented at ASH Annual Meeting 2017, Atlanta (Georgia), USA: Abstract 476.
  26. Bustoros M et al. Am Soc Clin Oncol Educ Book 2017; 37: 548–560.
  27. Bolen J et al. Blood 2017; 130: 2729.
  28. Grzegorz S et al. Blood 2007; 110: 2067.
  29. Rossi D et al. Clin Cancer Res 2009; 15: 995–1004.
  30. Zenz T et al. J Clin Oncol 2010; 28: 4473–4479.
  31. Woyach JA et al. J Clin Oncol 2017; 35: 1437–1443.
  32. VITRAKVI® (larotrectinib) Prescribing Information. Leitav: https://www.loxooncology.com/docs/general/vitrakvi.pdf (Accessed July 2020).
  33. Vaishnavi A et al. Cancer Discov 2015; 5: 25–34.
  34. GLEEVEC® (imatinib mesylate) Prescribing Information. Leitav: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf (Accessed July 2020).
  35. Tarlock K et al. Oncotarget 2018; 9: 26417–26430.
  36. Severson EA et al. Oncologist 2019; 24: 372–374.
  37. Chmielecki J et al. Cancer Res 2017; 77: 509–519.
  38. Pavlick D et al. Pediatr Blood Cancer 2017; 64: e26433.
  39. FoundationOne®Heme Specimen Instructions, 2018. Leitav: https://assets.ctfassets.net/vhribv12lmne/36S2Vq3BPqwaTLoww8gerj/78a3f27012a3b3ea9e3064561dc22a02/F1H_Specimen_Instructions.pdf (Accessed July 2020).